Suppr超能文献

脊髓刺激治疗顽固性心绞痛:疗效与成本效益的回顾性分析

Spinal cord stimulation for refractory angina pectoris: a retrospective analysis of efficacy and cost-benefit.

作者信息

Yu Wei, Maru Fikru, Edner Magnus, Hellström Kerstin, Kahan Thomas, Persson Hans

机构信息

Section of Cardiology, Division of Internal Medicine, Karolinska Institutet Danderyd Hospital, S-182 88 Stockholm, Sweden.

出版信息

Coron Artery Dis. 2004 Feb;15(1):31-7. doi: 10.1097/00019501-200402000-00005.

Abstract

BACKGROUND

Patients with refractory angina pectoris have severe symptoms despite optimal medication, but are not suitable for revascularisation. Spinal cord stimulation (SCS) has been used for treating refractory angina pectoris since 1985. The efficacy of SCS has been proven by randomised controlled trials and follow-up studies have shown that SCS is a safe treatment. The objective of the current study was to retrospectively analyse the clinical outcomes and cost-benefit of SCS in patients with refractory angina pectoris.

METHODS

Eighteen months after SCS implantation, the effects on Canadian Cardiovascular Society (CCS) functional level and acute symptom relief of 24 patients with permanent SCS were analysed by review of medical records. Nineteen of these 24 patients were able to report their anginal frequency, nitroglycerin consumption and subjective perception on physical activity and quality of life.

RESULTS

Angina frequency decreased from a median of 14.0 to 2.3 attacks/week (p < 0.01). Nitroglycerin intake decreased from a median of 27.5 to 1.5 doses/week (p < 0.01). Canadian Cardiovascular Society angina class improved from a median of three to two (p < 0.001). During a three-year period before SCS implantation, the hospitalisation rate and duration related to coronary artery disease increased progressively. The duration of hospitalisation increased from a median of three to 10 days/patient/year. In the year after SCS implantation the duration of hospitalisation decreased to a median of 0 day/patient/year (p < 0.001). The cost of hospital care due to coronary artery disease decreased significantly thereafter. The total cost of SCS procedure was recovered within 16 months after implantation, which is less than 40% of the device life span.

CONCLUSIONS

This retrospective study indicates that SCS treatment alleviates angina symptoms and improves quality of life. The treatment is also effective in preventing hospitalisations and saving costs in hospital care. A prospective study is warranted to confirm the current observations.

摘要

背景

尽管接受了最佳药物治疗,难治性心绞痛患者仍有严重症状,但不适合进行血运重建。自1985年以来,脊髓刺激(SCS)已被用于治疗难治性心绞痛。SCS的疗效已通过随机对照试验得到证实,随访研究表明SCS是一种安全的治疗方法。本研究的目的是回顾性分析SCS治疗难治性心绞痛患者的临床结局和成本效益。

方法

在SCS植入18个月后,通过查阅病历分析24例永久性SCS患者对加拿大心血管学会(CCS)功能水平和急性症状缓解的影响。这24例患者中有19例能够报告其心绞痛发作频率、硝酸甘油消耗量以及对体力活动和生活质量的主观感受。

结果

心绞痛发作频率从中位数每周14.0次降至2.3次(p<0.01)。硝酸甘油摄入量从中位数每周27.5剂降至1.5剂(p<0.01)。加拿大心血管学会心绞痛分级从中位数3级改善至2级(p<0.001)。在SCS植入前的三年期间,与冠状动脉疾病相关的住院率和住院时间逐渐增加。住院时间从中位数每年每位患者3天增加至10天。在SCS植入后的一年中,住院时间降至中位数每年每位患者0天(p<0.001)。此后,因冠状动脉疾病导致的住院费用显著降低。SCS手术的总成本在植入后16个月内收回,这不到设备使用寿命的40%。

结论

这项回顾性研究表明,SCS治疗可缓解心绞痛症状并改善生活质量。该治疗在预防住院和节省住院护理费用方面也有效。有必要进行前瞻性研究以证实当前的观察结果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验